Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Pinotbio Inc. is active in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions. This indicates a focused prosecution phase as the company seeks to secure its intellectual property. The firm is currently responding to these actions to advance its applications through the patent office.
The company's applications are being reviewed by 2 distinct examiners in 2 distinct art units. This distribution suggests that the portfolio covers different technical aspects of biotechnology that require specialized evaluation. With 2 distinct examiners, the company must manage two separate examination processes, each with its own set of technical requirements and examiner styles.
BRAUN, MADELINE E is the busiest examiner for this portfolio. This individual is currently overseeing 1 busiest examiner pending office action. Because there are 2 pending office actions in total, BRAUN, MADELINE E is responsible for a portion of the company's active matters. Practitioners should be prepared to address the specific feedback from BRAUN, MADELINE E while also managing the other pending action with a different examiner.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRAUN, MADELINE E | 1 | 68.0% | +25.7% |
| MIDDLETON, DANAYA L | 1 | 48.5% | +49.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18274864 | BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | BRAUN, MADELINE E | 20d |
| 18016331 | CONJUGATE IN WHICH FL118 DRUG IS LINKED TO ACID-SENSITIVE LINKER, AND IMMUNOCONJUGATE USING SAME | MIDDLETON, DANAYA L | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18274864 | BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | BRAUN, MADELINE E | 20d |
| 18016331 | CONJUGATE IN WHICH FL118 DRUG IS LINKED TO ACID-SENSITIVE LINKER, AND IMMUNOCONJUGATE USING SAME | MIDDLETON, DANAYA L | 34d |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18274864 | BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | BRAUN, MADELINE E | 1624 | §102§112 | Final Rejection | 20d | Pending | Jul 28, 2023 |
| 18016331 | CONJUGATE IN WHICH FL118 DRUG IS LINKED TO ACID-SENSITIVE LINKER, AND IMMUNOCONJUGATE USING SAME | MIDDLETON, DANAYA L | 1674 | §103§112Other | Final Rejection | 34d | Pending | Jan 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial